Experience real patient situations that progressively unfold, presented to a representative sample of 158 US oncologists who manage 11 or more patients monthly with non-Hodgkin’s lymphoma. Oncologists were presented with four patient case scenarios and asked to respond to open-ended questions concerning their choices of treatment regimens, factors that influenced their decisions, and barriers to optimal patient management. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of specific patient types.

Patient situations:

• Asymptomatic indolent lymphoma
• Elderly infirm patient with advanced follicular lymphoma
• Relapsed large cell lymphoma and
• Large cell lymphoma with compromised cardiac function

Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists’ decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

• Understand what occurs with actual patients
• Access the most up-to-date prescribing trends
• Gain actionable data for developing and improving your market strategies
• Pinpoint needs of your target audience
• Focus resources to maximize the effectiveness of your budget
• Understand where your product fits
• Understand where your competitor’s product fits
• Design messages to advance brand performance

Table of Contents

Executive Summary

Chapter 1: Introduction

Table 1. Treatment Options in Non-Hodgkin’s Lymphoma

Chapter 2: Respondent Demographics

Table 2. Eligibility Criteria for Survey Participation

Figure 2.1 Gender of Survey Respondents

Figure 2.2 Years since Medical School Graduation

Figure 2.3 Practice Settings

Figure 2.4 Practices in NCI Cancer Centers

Figure 2.5 Geographic Settings

Figure 2.7 Number of Physicians in Practice Groups

Figure 2.6 Survey Respondents by State’s Non-Hodgkin’s Lymphoma Mortality

Figure 2.7 Number of Physicians in Practice Groups

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

Chapter 3: Treatment of Asymptomatic Indolent Lymphoma

Figure 3.1 Initial treatment of asymptomatic indolent lymphoma

Figure 3.2 Treatment goals for this patient

Figure 3.3 Confidence in management of this patient

Figure 3.4 Most important barriers to optimal treatment

Figure 3.5 Treatment upon disease progression

Figure 3.6 Treatment on further disease progression

Figure 3.7 Factors influencing treatment

Chapter 4: Elderly Infirm Patient with Advanced Follicular Lymphoma

Figure 4.1 Approach to initial treatment of patient

Figure 4.2 Factors influencing treatment choice

Figure 4.3 Preferred next step

Figure 4.4 Treatment for disease progression

Figure 4.5 Contraindication to Zevalin (ibritumomab) use

Chapter 5: Patient with Relapsed Large Cell Lymphoma

Figure 5.1 Barriers to optimal care of large cell lymphoma

Figure 5.2 Confidence in treatment

Figure 5.3 First line treatment approach to patient with large cell lymphoma

Figure 5.4 Factors that influence treatment decision

Figure 5.5 Preferred R-CHOP regimen

Figure 5.6 Next step in management following R-CHOP

Figure 5.7 Treatment for progressing B-cell large cell lymphoma

Figure 5.8 Factors influencing treatment decision

Figure 5.9 Treatment following response then relapse from second-line therapy

Chapter 6: Patient with Large Cell Lymphoma with Compromised Cardiac Function

Figure 6.1 Confidence in treatment for large cell lymphoma with compromised cardiac function

Figure 6.2 Treatment approach for large cell lymphoma with compromised cardiac function

Figure 6.3 Factors influencing treatment of large cell lymphoma with compromised cardiac function

Figure 6.4 Further treatment for large cell lymphoma with compromised cardiac function

Figure 6.5 Second-line treatment for large cell lymphoma with compromised cardiac function

Chapter 7: Summary

Appendix A: Survey Instrument

 

List of Tables

List of Figures